Glenmark Readying Xolair Biosimilar Challenge
Glenmark has received US FDA clearance of an IND to start clinical studies with a proposed biosimilar version of Xolair. The Indian company appears confident of addressing any price-related challenges although the targeted launch is still some years away.
You may also be interested in...
Sorrento Therapeutics has gained exclusive licensing rights from China’s Mabtech to develop four biosimilar and biobetter products for oncology and auto-immune diseases in western markets and Japan. China’s homegrown biopharmaceutical company has shown another example of its research capability to develop new drugs for the global market.
Coronavirus Notebook: Fauci Calls For Restraint In Disclosing Early Data; Bipartisan Lawmakers Want Warp Speed Audit
Dispatches from a world turned upside down also include the conditional approval of remdesivir in South Korea.
Sun’s Q1 earnings were dented by provisions related to the generic pricing investigation settlement with the US Department of Justice of arm Taro, and the impact of pandemic-related lockdowns. Some clinic-administered products bore the brunt of lock-downs in parts of the US, though market share was unaffected.